ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

apripitant and palonosetron injectable emulsion

Its studies are mostly in Vomiting, led by Qilu Pharmaceutical.

Furthest: phase 1, since Sep 2, 20261 company-led study, 1 open or runningNext primary completion: Nov 2026 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Qilu Pharmaceutical11 open or runningphase 1since Sep 2, 2026Sep 2, 2026Nov 2026phase 1 · NCT07817004

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Sep 2, 2026First study: phase 1 study in VomitingFirst studyNCT07817004 · 42 planned

Ahead

  1. Nov 2026Primary completion: phase 1 study in VomitingNCT07817004

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07817004Vomiting1Not yet recruitingNov 202642

How it is read

Names in the registry

  • “apripitant and palonosetron injectable emulsion”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.